Any cut-off is a trade-off
They verify that each active ingredient complies with specifications set by the United States Pharmacopeia an independent, not-for-profit organization that sets quality and safety standards for medicine

Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome

Stimulate angiogenesis The BPC-157 peptide enhances the formation of new blood vessels (angiogenesis), thereby improving circulation, oxygen delivery, and cellular repair in damaged tissues
Starting injections without a proper diagnosis is just guessing, and it could end up hiding other serious health issues
or a metallic taste